PETER PIETSCHMANN: PUBLICATIONS ORIGINAL PAPERS

1. Pietschmann P, Schernthaner G, Luger A (1986) Effect of cholinergic muscarinic receptor blockade on human growth hormone(GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus. J Clin Endocrinol Metab 63: 389-393 IF=5.805

2. Pietschmann P, Schernthaner G, Prskavec F, Gisinger C, Freyler H (1987) No

evidence for increased growth hormone responses to growth hormone-releasing hormone in patients with diabetic retinopathy. Diabetes 36: 159-162 IF=9.019

3. Pietschmann P, Schernthaner G (1987) Effect of growth hormone releasing

hormone on growth hormone secretion in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 13-15 IF=5.177

4. Lang I, Schernthaner G, Pietschmann P, Kurz R, Stephenson JM, Templ H (1987)

Effects of sex and age on growth hormone response to growth hormone-releasing hormone in healthy individuals. J Clin Endocrinol Metab 65: 535-540 IF=5.805

5. Pietschmann P, Schernthaner G (1988) The effect of pirenzepine on growth

hormone and blood glucose levels in type I diabetes mellitus. Acta Endocrinol (Copenh) 117: 315-319 IF=2.421

6. Pietschmann P, Schernthaner G, Schnack C, Gaube S (1988) Serum

concentrations of laminin P1 in diabetics with advanced nephropathy. J Clin Pathol 41: 929-932 IF=1.657

7. Pietschmann P, Woloszczuk W, Panzer S, Kyrle P, Smolen J (1988) Decreased

serum osteocalcin levels in Phenprocoumon-treated patients. J Clin Endocrinol Metab 66: 1071-1074 IF=5.805

8. Pietschmann P, Schernthaner G, Woloszczuk W (1988) Serum osteocalcin levels

in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 31:892-895 IF=5.177

2

9. Pietschmann P, Machold KP, Woloszczuk W, Smolen JS (1989) Serum osteocalcin levels in patients with rheumatoid arthritis. Ann Rheum Dis 48: 654-657 IF=1.968

10. Resch H, Pietschmann P, Willvonseder R (1989) Estimated long-term effect of

calcitonin treatment of acute osteoporotic spine fractures. Calcif Tissue Int 45: 209-213 IF=1.976

11. Pietschmann P, Zielinski Ch, Woloszczuk W (1989) Serum osteocalcin levels in

breast cancer patients. J Cancer Res Clin Oncol 115: 456-458 IF=1.052

12. Pietschmann P, Resch H, Müller Ch, Woloszczuk W, Willvonseder R (1990)

Decreased serum osteocalcin levels in patients with liver cirrhosis. Bone Miner 8: 103-108 IF=2.082

13. Pietschmann P, Resch H, Woloszczuk W, Willvonseder R (1990) A circadian

rhythm of serum osteocalcin levels in postmenopausal osteoporosis. Eur J Clin Invest 20: 310-312 IF=1.922

14. Pietschmann P, Woloszczuk W, Pietschmann H (1990) Increased serum

osteocalcin levels in elderly females with vitamin D deficiency. Exp Clin Endocrinol 95: 275-278 IF=1.044

15. Pietschmann P, Kuzmits R, Schernthaner G (1990) Increased growth hormone

responses to growth hormone releasing hormone and thyrotropin releasing hormone in patients with metastatic testicular cancer. Horm Metabol Res 22: 109-113 IF=1.465

16. Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R (1990)

Peripheral bone mineral content in patients with fatty liver and hepatic cirrhosis. Scand J Gastroenterol 25: 412-416 IF=2.336

17. Resch H, Pietschmann P, Bernecker P, Krexner E, Willvonseder R (1990)

Broadband ultrasound attenuation: a new diagnostic method in osteoporosis. Am J Roentgenol 155: 825-828 IF=1.237

3

18. Resch H, Pietschmann P, Krexner E,Woloszczuk W, Willvonseder R (1990) Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta endocrinol (Copenh) 123: 14-18 IF=2.421

19. Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R (1991)

Decreased bone mineral content in patients under anticoagulant therapy with phenprocoumon. Eur Heart J 12: 439 – 441 IF=3.210

20. Pietschmann P, Knoflach P, Wolosczczuk W (1991) Increased serum osteocalcin

levels in patients with lactase deficieny. Am J Gastroenterol, 86: 72-74 IF=2.945

21. Pietschmann P, Müller Ch, Woloszczuk W (1991) Serum osteocalcin levels are

decreased in patients with acute viral hepatitis. Bone Miner, 13: 251-256 IF=2.082

22. Pietschmann P, Schernthaner G, Stephenson J, Lang I, Templ H (1991) Enhanced

growth hormone responses to growth hormone releasing hormone in male type I diabetic patients. Horm Metabol Res, 23: 379-382 IF=1.465

23. Pietschmann P, Vychytil A, Woloszczuk W, Kovarik J (1991) Bone Metabolism

in patients with functioning kidney grafts: increased serum levels of osteocalcin despite normalisation of kidney function. Nephron 59: 533 – 536 IF=1.696

24. Resch H, Pietschmann P, Bernecker P, Krexner E, Kromer F, Willvonseder R

(1991) Peripheral and axial bone mass in Austrian free climbers. Klin Wochenschr 69: 303-306 IF=1.050

25. Pietschmann P, Niederle B, Anvari A, Woloszczuk W (1991) Serum osteocalcin

levels in primary hyperparathyroidism. Klin Wochenschr 69: 351-353 IF=1.050

26. Pietschmann P, Resch H, Krexner E, Woloszczuk W, Willvonseder R (1991)

Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis. Acta med Austriaca 18: 114 – 116 IF=0.291

4

27. Resch H, Pietschmann P, Krexner E, Bernecker P, Willvonseder R (1991) Bone mass and bone diminution of the axial and peripheral skeleton in normal and osteoporotic Austrian females. Acta med Austriaca 18: 117 – 120 IF=0.291

28. Pietschmann P, Pils P, Woloszczuk W, Maerk R, Lessan D, Stipicic J (1992)

Increased serum osteocalcin levels in patients with paraplegia. Paraplegia 30: 204 – 209 IF=0.487

29. Bernecker P, Pietschmann P, Winkelbauer F, Krexner E, Resch H, Willvonseder

R (1992). The spine deformity index in osteoporosis is not related to bone mineral and ultrasound measurements. Brit J Radiol 65: 393 – 396 IF=1.067

30. Resch H, Pietschmann P, Woloszczuk W, Krexner E, Bernecker P, Willvonseder

R (1992) Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest 22: 542 – 545 IF=1.922

31. Resch H, Bernecker P, Pietschmann P, Krexner E, Willvonseder R (1992)

Beeinflussung der Bioverfügbarkeit von retardiertem Natriumfluorid durch Kalzium und den Zeitpunkt der Nahrungsaufnahme bei Patienten mit Osteoporose. Osteologie 1: 32 - 36

32. Pietschmann P, Cush JJ, Lipsky PE, Oppenheimer Marks N (1992) Identification

of subsets of human T cells capable of enhanced transendothelial migration. J Immunol 149: 1170 – 1178 IF=7.145

33. Resch H, Pietschmann P, Bernecker P, Krexner E, Willvonseder R (1992) The

influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density. Clin Investig 70: 426 – 429 IF=0.479

34. Cush JJ, Pietschmann P, Oppenheimer-Marks N, Lipsky PE (1992) The intrinsic

migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. Arthritis Rheum 35: 1434 – 1444 IF=7.054

35. Farsoudi KH, Pietschmann P, Cross HS, Peterlik M (1993) Suramin is a potent

inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro. J Pharmacol Exp Ther 264: 579 – 583 IF=3.300

5

36. Pietschmann P, Farsoudi KH, Hoffmann O, Klaushofer K, Hörander H, Peterlik

M (1993) Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 14: 167 – 172 IF=3.961

37. Kotzmann H, Bernecker P, Hübsch P, Pietschmann P, Woloszczuk W, Svoboda

T, Geyer G, Luger A (1993) Bone mineral density and parameters of bone metabolism in patietns with acromegaly. J Bone Miner Res 8: 459 – 465 IF=6.477

38. Sachs G, Spiess K, Moser G, Kautzky A, Luger A, Pietschmann P, Schernthaner

G, Prager R (1993) Hormonal and blood glucose responsiveness as an indicator of specific emotional arousal in type 1 diabetics. J Psychosomatic Res 37: 1 – 11 IF=1.573

39. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R,

Müller M (1993) Thrombogenic factors are related to urinary albumin excreation in type 1 (insulin-dependent) diabetic patients. Diabetologia 36: 1045 – 1050 IF=5.177

40. Schnack Ch, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G

(1994) Apolipoprotein (a) levels and atherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus. Nephron 66: 273 – 277 IF=1.696

41. Knöbl P, Schernthaner G, Schnack Ch, Pietschmann P, Proidl S, Prager R,

Vukovich T (1994) Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thrombosis and Haemostasis 71: 692 – 697 IF=4.983

42. Knöbl P, Pietschmann P, Schnack C, Prager R, Schernthaner G (1994).

Apolipoprotein (a) levels in patients with type I diabetes mellitus are unrelated to metabolic control or vascular disease. Wien Klin Wochenschr 106: 728 – 732 IF=0.588

43. Spiess K, Sachs G, Moser G, Pietschmann P, Schernthaner G, Prager R (1994)

Psychological moderator variables and metabolic control in recent onset type 1 diabetic patients - a two year longitudinal study. J Psychosom Res 38: 249 - 258 IF=1.573

6

44. Resch H, Pietschmann P, Kudlacek S, Woloszczuk W, Krexner E, Bernecker P, Willvonseder R (1994) Influence of sex and age on biochemical bone metabolism parameters. Mineral Electroyte Metab, 20: 117 – 121 IF=1.465

45. Erlacher L, Teufelsbauer H, Bernecker P, Pietschmann P, Weissel M (1994) A

study comparing serum fluoride levels after administration of monofluorphosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations. Clin Investig 72: 1082 – 1085 IF=0.963

46. Rimpfel T, Schmidinger H, Pidlich J, Wolosczuk W, Pietschmann P (1994)

Serum levels of parathyroid hormone in patients with hypertrophic cardiomyopathy. Osteologie 3: 197 - 200

47. Kudlacek S, Jahandideh-Kazempour S, Graninger W, Willvonseder R,

Pietschmann P (1995) Differential expression of various T cell surface markers in young and elderly subjects. Immunobiology 192: 198 – 204 IF=2.276

48. Griesmacher A, Kindhauser M, Andert SE, Schreiner W, Toma C, Knoebl P,

Pietschmann P, Prager R, Schnack C, Schernthaner G, Mueller M (1995) Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 98: 469 – 475 IF=4.977

49. Spiess K, Sachs G, Pietschmann P, Prager R (1995) A program to reduce onset

distress in unselected type I diabetic patients: effects on psychological variables and metabolic control. Eur J Endocrinol 132: 580 – 586 IF=2.421

50. Krexner E, Resch H, Pietschmann P, Bernecker P, Wolosczuk W, Vukovich T,

Geyer G, Willvonseder R (1996) Vitamin D status in residents of a long-term-care geriatric hospital in Vienna. Osteologie 5: 13 – 18

51. Stohlawetz P, Kolussi T, Jahandideh-Kazempour S, Kudlacek S, Graninger W,

Willvonseder R, Pietschmann P (1996) The effect of age on the transendothelial migration of human T lymphocytes. Scand J Immunol 44: 530 – 534 IF=1.740

52. Redlich K, Pietschmann P, Stulc T, Peterlik M (1997) Comparative study on the

effect of calcium channel blockers on basal and parathyroid hormone-induced bone resorption in vitro. Pharmocol Toxicol, 80: 262 – 265 IF=1.263

7

53. Erlacher L, Kettenbach J, Kiener H, Graninger W, Kainberger F, Pietschmann P (1997) Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density. Wien Klin Wochenschr 109/8: 270 – 274 IF=0.588

54. Schiller C, Gruber R, Redlich K, Ho GM, Katzgraber F, Willheim M,

Pietschmann P, Peterlik M (1997) 17β-Estradiol antagonizes effects of 1α,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures. Endocrinology 138: 4567 – 4571 IF=5.365

55. Schiller C, Gruber R, Ho GM, Redlich K, Gober HJ, Katzgraber F, Willheim M,

Hoffmann O, Pietschmann P, Peterlik M (1998) Interaction of triiodothyronine with 1α,25-dihydroxyvitamin D3 on interleukin-6 dependent osteoclast-like cell formation in mouse bone marrow cell cultures. Bone 22: 341 – 346 IF=3.961

56. Graninger M, Dirnberger E, Kainberger F, Bernecker P, Graninger W, Smolen J,

Pietschmann P (1998) Comparison of spinal and femoral dual energy X-ray absorptiometry (DXA) in men with primary and secondary osteoporosis. Osteologie 7: 48 - 52

57. Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M (1998)

The effect of alendronate on cytokine production, adhesion molecule expression and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 63: 325 - 330. IF=1.976

58. Stohlawetz P, Hahn P, Köller M, Hauer J, Resch H, Smolen J, Pietschmann

(1998) Immunophenotypic characterization of monocytes in elderly subjects. Scand J Immunol 48: 324 – 326 IF=1.740

59. Aringer M, Kiener HP, Köller MD, Artemiou O, Zuckermann A, Wieselthaler G,

Klepetko W, Seidl G, Kainberger F, Bernecker P, Smolen JS, Pietschmann P (1998) High turnover bone disease following lung transplantation. Bone 23: 485 – 488 IF=3.961

60. Kerschan-Schindl K, Uher E, Preisinger E, Pietschmann P (1999) Anwendung des

in die deutsche Sprache übersetzten Osteoporosis Quality of Life Questionnaire (OQLQ). Wien Klin Wochenschr 111: 608 – 611 IF=0.588

8

61. Willheim M, Thien R, Schrattbauer K, Banja E, Holub M, Gruber R, Baier K, Pietschmann P, Reinisch W, Scheiner O, Peterlik M (1999) Regulatory effects of 1α,25-Dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 84: 3739 – 3744 IF=5.805

62. Grisar G, Travica S, Metka M, Pietschmann P (1999) Hormonersatztherapie mit

17β-Östradiol-Dydrogesteron: Ergebnisse einer dreimonatigen Anwendungsbeobachtung. Wien Klin Wochenschr 111: 1035 – 1043 IF=0.588

63. Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M (2000) Surface

markers and transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 35: 213 – 224 IF=1.762

64. Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P,

Kainberger F, Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 59: 308 – 310 IF=1.968

65. Pietschmann P, Stöckl J, Draxler S, Majdic O, Knapp W (2000) Functional and

phenotypic characterization of dendritic cells generated in human plasma supplemented medium. Scand J Immunol 51: 377 – 383 IF=1.740

66. Aringer M, Vierhapper H, Graninger MT, Bernecker P, Smolen JS, Pietschmann

P (2000) Succsessful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency. Wien Klin Wochenschr 112(7): 334-337 IF=0.588

67. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber

K, Lorenc R, Pietschmann P, Silverman S, Felsenberg D, Vandormael K, Daifotis A, Lombardi A (2000) Alendronate treatment of osteoporosis in men. N Engl J Med 343: 604 – 610 IF=28.857

68. Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P (2001)

Phenotypic characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 3: 127 – 132 IF=5.036

9

69. Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder R, Peterlik M (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31: 444 – 451 IF=1.922

70. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G (2001) A

comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37: 1247 – 1252 IF=3.501

71. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer

C, Kato S, Cross HS (2001) Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429-1435 IF=4.118

72. Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger

E, Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 36: 1749-1759 IF=1.762

73. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B,

Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002) Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46: 785 – 792 IF=6.841

74. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W,

Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002). Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29: 1430 – 1436 IF=2.910

75. Lernbass I, Wutzl A, Grisar J, Schett G, Redlich K, Spitzauer S, Grampp S, Imhof

H, Peterlik M, Pietschmann P (2002) Quantitative ultrasound in the assessment of bone status of patients suffering from rheumatic diseases. Skeletal Radiol 31: 270 – 276 IF=0.695

10

76. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003)

Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681 -686 IF=3.961

77. Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Biegelmayer C,

Pacher R, Maurer G, Fialka-Moser V, Pietschmann P (2003) Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transpl 22: 843 – 850 IF=2.179

78. Sipos W, Duvigneau CJ, Pietschmann P, Willheim M, Höller K, Hartl RT, Wahl

K, Steinborn R, Gemeiner M, Schmoll F (2003) Parameters of humoral and cellular immunity following vaccination of pigs with a European modified-live strain of porcine reproductive and respiratory syndrome virus (PRRSV), Viral Immunol 16: 335 – 346 IF=1.190

79. Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M,

Woloszczuk W, Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 38: 1119 – 1127 IF=2.493

80. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A,

Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of non-traumatic fracture. JAMA 291: 1108 – 1113 IF=21.455

81. Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S,

Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A (2004) Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. J Nephrol 17: 87 – 94 IF=1.025

82. Kerschan-Schindl K, Mitterbauer M, Füreder W, Kudlacek S, Grampp S,

Biegelmayer C, Fialka-Moser V, Pietschmann P, Kahls P (2004) Post- transplant complications – Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplantation 34:491-496 IF=2.172

11

83. Sipos W, Duvigneau JC, Willheim M, Schilcher F, Hartl RT, Hofbauer G, Exel B,

Pietschmann P, Schmoll F (2004) Systemic cytokine profile in feeder pigs suffering from natural postweaning multisystemic wasting syndrome (PMWS) as determined by semiquantitative RT-PCR and flow cytometric intracellular cytokine detection. Vet Immunol Immunopathol 99: 63 – 71 IF=1.652

84. Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner

CW, Zierhut B, Wagner L, Pietschmann P, Smolen JS (2004) Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 63: 1632-1637 IF=3.827

85. Sipos W, Willheim M, Hofbauer G, Pietschmann P (2005) Evaluation of the

suitability of monoclonal antibodies for flow cytometric intracellular cytokine detection in peripheral blood lymphocytes. J Vet Med A 52: 55-60 IF=0.558

86. Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P,

Thomas R (2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 7: R230-40 IF=5.036

87. Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P

(2005) Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40: 532 – 535 IF=2.857

88. Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K,

Dudczak R, Willheim M (2005) Relation of anti-TPO antibody titre and T-lymphocyte cytokine production patterns in Hashimoto’s thyroiditis. Clin Endocrinol 63: 191 – 196 IF=2.767

89. Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions of

1α,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J Allergy Clin Immunol 116: 683 – 689 IF=6.831

90. Sipos W, Duvigneau JC, Pietschmann P, Schilcher F, Hofbauer G, Hartl RT,

Schmoll F (2005) Porcine dermatitis and nephropathy syndrome (PDNS) is associated with a systemic cytokine expression profile indicative of proinflammation and a Th1 bias. Vet Immunol Immunopathol, A52: 382-387 IF=1.652

12

91. Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Hartl R, Exel B,

Dobretsberger M, Pietschmann P (2005) Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1α,25(OH)2D3. J Vet Med A52: 382-387 IF=0.558

92. Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S,

Strele A, Obermayer-Pietsch B (2005) Molecularly-defined malabsorption, milk consumption and anthropometric differences in adult males. Q J Med 98: 857-863 IF=2.395

93. Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger

F, Peterlik M, Pietschmann P (2006) Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77 (1): 75-83 IF=3.652

94. Fischer P, Gruenblatt E, Pietschmann P, Tragl KH (2006) Serotonin Transporter

Polymorphism and LDL-Cholesterol. Mol Psychiatry 11 (8): 707-709 IF=5.539

95. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P,

Ewers R, Baumann A. (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118 (15-16): 473-478 IF=0.588

96. Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E,

Stettner H, Grimm G, Lind P, Pietschmann P (2006) Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36: 566-573 IF=2.701

97. Brosch S, Shehata M, Hofbauer G, Peterlik M, Pietschmann P (2006) Alendronate

stimulates expression of functional surface molecules ICAM-1, HLA-DR and B7-2 on human monocytes. Osteol 15: 188-196

98. Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P,

Kudlacek S, Obermayer-Pietsch B (2007) Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. J Endocrinol Invest 30 (1): 46-51 IF=1.496

99. Rauner M, Winzer M, Stupphann D, Krenbek D, Pietschmann P (2007) RANKL

and OPG gene expression in bone marrow stromal cells and calvarial osteoblasts in mouse and rat. Osteol 16: 19-28

13

100. Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D,

Viidik A (2007) Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol 42: 1099-1108 IF=2.879

101. Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik

E, Gallowitsch HJ, Lind P, Pietschmann P (2008) High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 18:27-33. IF=2.692

102. Kerschan-Schindl K, Ruzicka M, Mahr S, Paireder M, Krestan C, Gleiss A,

Bieglmayer C, Fialka-Moser V, Pacher R, Grimm M, Pietschmann P (2008) Unexpected low incidence of vertebral fractures in heart transplant recipients: analysis of bone turnover. Transpl Int 21:255-262. IF=2.300

103. Sipos W, Rauner M, Skalicky M, Viidik A, Hofbauer G, Schett G, Redlich K,

Lang S, Pietschmann P. (2008) Running has a negative effect on bone metabolism and proinflammatory status in male aged rats. Exp Gerontol 43: 578-583 IF=2.879

104. Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W,

Pietschmann P (2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 116:491-495

IF=1.745 105. Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, Resch H,

Pietschmann P (2008) Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatology Int 28:987-495

IF=1.270 106. Rauner M, Sipos W, Pietschmann P (2008) Age-dependent Wnt gene expression

in bone and during the course of osteoblast differentiation. Age 30:273-282 IF=2.925

107. Cejka D., Benesch T., Krestan C., Roschger P., Klaushofer K., Pietschmann P., Haas M. (2008) Effect of teriparatide on early bone loss after kidney transplantation. Am J Transpl. 8;1864-1870

IF=6.423

14

108. Rauner M, Sipos W, Göttsch C, Wutzl A, Foisner R, Pietschmann P, Hofbauer LC (2009) Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res 24:78-86 IF=6.443

109. Rauner M, Stupphann D, Haas M., Fert I, Glatigny S, Sipos W, Breban M,

Pietschmann P. (2009) The HLA-B27 transgenic rat, a model of spondyloarthritis, has a decreased bone mineral density and an increased RANKL-to-OPG mRNA ratio. J Rheumatol 36:120-126 IF=3.3.282

110. Muschitz C, Patsch J, Buchinger E, Edlmayr E, Nirnberger G, Evdokimidis V, Waneck R, Pietschmann P, Resch H. (2009). Prevalence of vertebral fracture in elderly men and women with osteopenia. Wien Klin Wochenschr 121(15-16):528-536 IF: 0.857

111. Kerschan-Schindl K, Thalmann M, Sodeck G, Skenderi K, Matalas AL, Grampp S, Ebner C, Pietschmann P. (2009). A 246-km continuous running race causes significant changes in bone metabolism. Bone 45(6):1079-1083 IF: 4.145

112. Sarahrudi K, Mousavi M, Thomas A, Eipeldauer S, Vécsei V, Pietschmann P,

Aharinejad S (2010). Elevated levels of macrophage colony-stimulated factor in human fracture healing. J Orthop Res 28:671-676 IF: 3.112

113. Azizi-Semrad U, Krenbek D, Hofbauer G, Karanikas G, Maldonado-Gonzalez M,

Pietschmann P, Willheim M. (2010). Cytokine profiling of human peripheral blood CD4+ T-lymphocytes reveals a new IL-6 producing Th-subpopulation (Th6). Eur Cytokine Netw 21(2):105-115

IF: 2.984

114. Wutzl A, Rauner M, Seemann R, Millesi W, Krepler P, Pietschmann P, Ewers R. (2010). Bone morphogenetic proteins 2, 5 and 6 in combination stimulate osteoblasts but not osteoclasts in vitro. J Orthop Res 28:1431-1439

IF: 3.112 115. Pietschmann P, Azizi-Semrad U, Pils K, Fahrleitner-Pammer A, Resch H, Dobnig

H (2010) Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior’s residences. Wien Klin Wschr 122:532-537 IF:0.955

15

116. Stelzer I, Fuchs R, Schraml E, Quan P, Hansalik M, Pietschmann P, Quehenberger F, Skalicky M, Viidik A, Schauenstein K (2010). Decline of bone marrow-derived hematopoietic progenitor cell quality during aging in the rat. Exp Aging Res 36:359-370 IF: 0.981

117. Winzer M, Rauner M, Pietschmann P (2010) Glycitein decreases the generation of

murine osteoclasts and increases apoptosis. Wien Med Wochenschr 160 (17-18):446-451.

118. Wutzl A, Gruber R, Brozek W, Hofbauer G, Lernbass I, Brosch S, Pietschmann P

(2010). Mechanisms involved in the inhibition of osteoclast generation by the benzothiophene SERM LY117018. Wien Klin Wochenschr 122:626-632. IF: 0.955

119. Patsch JM, Kiefer FW, Varga P, Pail P, Rauner M, Stupphann D, Resch H, Moser

D, Zysset PK, Stulnig TM, Pietschmann P. (2011). Increased bone resorption and impaired bone microarchitecture in short-termin and extended high-fat-diet induced obesity. Metabolism 60 (2):243-249 IF: 2.588

120. Patsch JM, Kohler T, Berzlanovich A, Muschitz C, Bieglmayr C, Roschger P,

Resch H Pietschmann P. (2011). Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res 26 (7):1584-1592, 2011 IF: 6.043

121. Sipos W, Kralicek E, Rauner M, Duvigneau C, Worliczek H, Schamall D, Hartl

R, Sommerfeld-Stur I, Dall’Ara E, Varga P, Resch H, Zyssett P, Pietschmann P (2011). Bone and cellular immune system of multiparous sows are insensitive to ovariectomy and nutritive calcium shortage. Horm Metab Res 43:404-409, 2011 IF:2.686

122. Sipos W, Zysset P, Kostenuik P, Mayrhofer E, Bogdan C, Rauner M, Stolina M, Dwyer D, Sommerfeld-Stur I, Pendl G, Resch H, Dall’Ara E, Varga P, Pietschmann P (2011). OPG-Fc treatment in growing pigs leads to rapid reduction in bone resorption markers, serum calcium, and bone formation markers. Horm Metab Res 43:944-949 IF:2686

123. Kerschan-Schindl K, Riss P, Krestan C, Rauner M, Bieglmayer C, Gleiss A,

Fialka-Moser V, Niederle B, Pietschmann P (2012) Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm Metab Res 44:476-481 IF:2686

16

124. Herman S, Krenbek D, Klimas M, Bonelli M, Steiner CW, Pietschmann P,

Smolen JS, Scheinecker C (2012) Regulatory T cells form stable and long-lasting cell cluster with myeloid dendritic cells (DC). Int Immunol 24:417-426 IF: 3.415

125. Schamall, D., P. Pietschmann, D. Moser, M. Dockner, and M. Teschler-Nicola

(2012) Diagnosis of contact injuries in a mediaeval skeleton analysed by µCT and histology. Wien Med Wochenschr 162:386-393

126. Kerschan-Schindl K, Patsch J, Kudlacek S, Gleiss A, Pietschmann P (2012)

Measuring quality of life with the German osteoporosis quality of life questionnaire in women with osteoporosis. Wien Klin Wochenschr 124:532-537. IF: 0.955

127. Misof BM, Patsch J, Roschger P, Muschitz C, Gamsjäger S, Paschalis P, Prokop

E, Klaushofer K, Pietschmann P, Resch H. (2014) Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 29:440 - 449 IF: 6.128

128. Rauner M, Föger-Samwald U, Kurz MF, Brünner-Kubath C, Schamall D, Kapfenberger A, Varga P, Kudlacek S, Wutzl A, Höger H, Zysset PK, Shi GP, Hofbauer LC, Sipos W, Pietschmann P (2014). Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone 64:281-287 IF: 3.823

129. Kocijan R, Muschitz C, Fahrleitner-Pammer A, Amrein K, Pietschmann P,

Haschka J, Dinu S, Kapiotis S, Resch H (2013) Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta. J Clin Endocr Metab, epub ahead of print IF:6.430

130. Dovjak P, Dorfer S, Föger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P. Serum levels of sclerostin and dickkopf-1:Effects of age, gender, and fracture status. Gerontology, accepted IF: 2.676

131. Gfrerer L, Shubinets V, Hoyos T, Nguyen C, Pietschmann P, Morton C, Maas R,

Liao E. Requirement of specc1lb in facial priminence integration and formation of the lower jaw.Plastic and Reconstructive Surgery, accepted IF: 3.535

17

REVIEWS, EDITORIALS, CASE REPORTS IN PEER REVIEWED JOURNALS:

1. Pietschmann P (1990) Osteokalzin. Wien Med Wschr 140: 493-494

2. Pietschmann P (1995) Wachstumshormon, Prolaktin und Knochenstoffwechsel. J Miner Stoffwechs 2: 14 - 16

3. Pietschmann P, Aringer M (1996) Transplantationsosteopathie. J Miner

Stoffwechs 3: 13 - 15

4. Pietschmann P (1996) Kortison-assoziierte Osteopathien. J Miner Stoffwechs 3: 6 - 7

5. Pietschmann P (1997) Klinik und Diagnose der Arthritis urica. Wien med Wschr

147: 375 - 376

6. Pietschmann P (1998) Calcitonin in der Osteoporosetherapie. J Miner Stoffwechs 5: 29 - 30

7. Pietschmann P, Peterlik M (1999) Pathophysiologie und Therapie der

Osteoporose. Radiologe 39: 228 – 234 IF=0.505

8. Pietschmann P (1999) Dem Osteoporose-Risikopatienten auf der Spur. J Miner

Stoffwechs 1/1999: 5 – 6

9. Pietschmann P, Peterlik M (1999) Pathophysiologie der Osteoporose. Wien med Wschr 149: 454 – 462

10. Aringer M, Pietschmann P (1999) Osteopathien nach Lungentransplantation. J

Miner Stoffwechs 6/4: 7 – 10

11. Kudlacek S, Resch H, Pietschmann P, Willvonseder R (1999) Hormones and osteoporosis in the aging male. The Aging Male 2: 1 – 6

12. Aringer M, Vierhapper H, Graninger MT, Bernecker P, Smolen JS, Pietschmann

P (2000) Successful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency. Wien Klin Wochenschr 112: 334 – 337 IF: 0.885

13. Grisar J, Pietschmann P (2000) Sekundäre Osteoporosen. J Miner Stoffwechs 7/2:

16 – 19

18

14. Kudlacek S, Willvonseder R, Stohlawetz P, Hahn P, Pietschmann P (2000)

Immunology and aging. The aging male 3: 137 – 142

15. Mikosch P, Pietschmann P, Kainberger F, Gallowitsch HJ, Lind P (2001) Morbus Paget oder fibröse Dysplasie des Radius? Ein Fallbericht. Wien Med Wschr 151: 295-299

16. Resch H, Gollob E, Kudlacek S, Pietschmann P (2001) Die Osteoporose beim

Mann. Wien Med Wschr 151: 457-463

17. Pietschmann P (2001) Geschlechtsunterschiede bei Gelenkserkrankungen: pathophysiologische Grundlagen. Wien Med Wschr 151: 573-575

18. Schmaldienst S, Dittrich E, Pietschmann P, Niederle B, Becherer A, Watschinger

B (2001) A patient with evidence of two underlying diseases causing hypercalaemia. Nephrol Dial Transplant 16: 2423-2425 IF: 3.371

19. Mitringer A, Pietschmann P (2002) Osteoporose bei prämenopausalen Frauen.

Wien Med Wschr 152:586-590

20. Pietschmann P, Grisar J, Travica S (2002) Kardiovaskuläre Aspekte der Hormonersatz-Therapie. J Miner Stoffwechs 9: 19 – 21

21. Pietschmann P: Editorial: Überraschende Ergebnisse von der Women’s Health

Initiative (2002) J Miner Stoffwechs 9: 5

22. Grisar J, Pietschmann P (2002) Heparininduzierte Schwangerschaftsosteoporose: Fallbericht und Literaturüberblick. J Miner Stoffwechs 9: 19-21

23. Mitringer A, Pietschmann P (2002) Osteoporose bei prämenopausalen Frauen.

Wien Med Wschr 152: 586 - 590

24. Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose. Wien Med Wschr 152: 596 - 612

25. Brosch S, Redlich K, Pietschmann P. (2003) Pathogenese der Osteoporose bei

chronischer Polyarthritis. Acta Med Austriaca 30: 1 – 5 IF=0.268

26. Pietschmann P, Willheim M, Peterlik M (2003) Bedeutung von Vitamin D im

Immunsystem. J Miner Stoffwechs 10 (3) 13 – 15

19

27. Pietschmann P, Kudlacek S, Peterlik M (2004) Pathogenese und Therapie der Osteoporose beim Mann. J Miner Stoffwechs 11 (suppl 2) 12 – 14

28. Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender specific

aspects. Wien Med Wschr 154/17-18: 411- 415

29. Pietschmann P, Kerschan-Schindl K (2004) Knochenqualität - wissenschaftliche Aspekt versus praktische Relevanz. J Miner Stoffwechs 11: 24 – 26

30. Pietschmann P. (2005) Editorial: Osteoporose – eine vernachlässigte

Erkrankung?. Wien Klin Wochenschr 117/1-2: 5-6 IF=0.885

31. Krenbek D, Bernecker PM, Pietschmann P (2006) Osteomalazie als Ursache für

Sprunggelenksschmerzen: Fallbericht J Miner Stoffwechs 13(3): 88-90

32. Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy Immunol 143: 31-48 IF=2.160

33. Patsch J, Muschitz C, Resch H, Pietschmann P (2007) Of mice and men:

pathophysiology of male osteoporosis. J Mens Health Gend 4(1): 87-93

34. Bröll H, Resch H, Pietschmann P, Sieghart S, Dobnig H, Erlacher L, Finkenstedt G, Holzer G, Pecherstorfer M, Pirich C (2007) Konsensus-Statement: Therapie der postmenopausalen Osteoporose - Anwendungsbereiche von parenteralen Bisphosphonaten. J Miner Stoffwechs 1: 45-48

35. Sipos W, Pietschmann P., Rauner M (2008) Strategies for novel therapeutic

approaches targeting ytokines and signaling pathways of osteoclasto-and osteoblastgenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 15(2): 127-136 IF=4.944

36. Stupphann D, Pietschmann P (2008) Sekundäre Osteoporose – Abgrenzung zur

primären Osteoporose. J Miner Stoffwechs 15(1): 2-5

37. Pieschmann P., Rauner M., Sipos W., Kerschan-Schindl K. (2009) Osteoporosis: an age-related and gender-specific disease. Gerontology 55:3-12 IF=1.358

38. Müller M. Pietschmann P. (2008) Parathyroid hormone analogues in the therapy of osteoporosis. Wien Klin Wochenschr 120 (11-12):321-324. IF=0.885

20

39. Pietschmann P., Rauner M., Sipos W. (2009) Pathophysiology of Osteoporosis. Wien Med Wochenschr. 159 (9-10):230-234

40. Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig

H, Klaushofer K (2009). Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009. Wien Med Wochenschr 159 (122): 1-34

41. Maldonado-Gonzalez E, Pietschmann P (2009) Osteoinmunologia: La

importancia del sistema inmunologico en la patofisiologia del hueso: un resumen. Revista Argentina de Osteología (3): 4-15

42. Pinter G, Likar R, Anditsch M, Bach M, Böhmer F, Friedrich M, Frühwald T,

Gosch M, Gugerell M, Lampl C, Marksteiner J, Pietschmann P, Pils K, Schirmer M (2010). Problemfelder in der Schmerzmessung und Schmerztherapie im Alter. Wien Med Wochenschr 160/9-10:235-246

43. Pietschmann P, Patsch JM, Schernthaner G (2010). Diabetes and Bone. Horm Metab Res 42:763-768. IF:2.686

44. Maldonado-Gonzales E, Pietschmann P (2010). An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases. Wien Med Wochenschr 160(17-18):458-463.

45. Pietschmann P (2010). Editorial:osteoimmunology. Wien Med Wochenschr 160 (17-18):437

46. Deutschmann J, Patsch J, Valentinitsch A, Pietschmann P, Varga P, Dall’Ara E, Zysset P, Weber GW, Resch H, Kainberger F.(2010). Research Network Osteology Vienna: Hochauflösende und Mikro-Computertomographie in der Wiener Osteologie. J Miner Stoffwechs 17(3):104-109

47. Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, Klaushofer K. (2010). Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose: Addenum 2010. Wien Med Wochenschr 160(21-22):586-589

48. Diesner SC, Untersmayr E, Pietschmann P, Jensen-Jarolim E (2011). Food allergy: Only a pediatric disease? Gerontology 57(1):28-32 IF: 1.661

49. Azizi-Semrad U, Grillari J, Grubek-Loebenstein B, Pietschmann P .(2011). Biogerontology in Austria. Biogerontology 12(1):3-10 IF: 2.816

50. Patsch JM, Deutschmann J, Pietschmann P (2011). Gender aspects of osteoporosis and bone strength. Wien Med Wochenschr 161/5-6:117-123

21

51. Kerschan-Schindl K, Pietschmann P (2011) Rehabilitation bei Osteoporose. Phys Med Rehab Kuror 21: 139-150 IF: 0.357

52. Pietschmann P. (2012) Editorial: Morbus Paget. J Miner Stoffwechs 19:2, p 61

53. Gosch M, Kammerlander C, Pils K, Lechleitner M, Benvenuti-Falger U, Roth T, Joosten-Gstrein B, Pietschmann P (2012) Osteoporotic treatment options in geriatric patients. Z Gerontol Geriatr, 45(5):417-28 IF:0.613

54. Pietschmann P, Föger-Samwald U (2012) FRAX® - Was ist das? Skriptum Kongressjournal der Wiener Medizinischen Wochenschrift 12:18-19

55. Rauner M, Sipos W, Thiele S, Pietschmann P (2013) Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol 160:114-125 IF:2.403

56. Pietschmann P, Föger-Samwald U, Sipos W, Rauner M (2013) The role of

cathepsins in osteoimmunology. Critical ReviewsTM in Eukaryotic Gene Expression 23:11-26 IF:2.065

57. Föger-Samwald U, Pietschmann P (2013) Gene expression analyses for

osteoporosis research. Osteologie 1:25-31

58. Lechleitner M, Pils K, Roller-Wirnsberger R, Beubler E, Gasser R, Mrak P, Hoppichler F, Pietschmann P (2013) Diabetes und Osteoporose – Pathophysiologische Interaktionen und klinische Bedeutung für geriatrische Pathienten. Z Gerontol Geriat 46:390-397 IF:0.736

59. Kerschan-Schindl K, Haschka J, Obermayer-Pietsch B, Gasser RW, Dimai HP,

Fahrleitner-Pammer A, Dobnig H, Roschger P, Preisinger E, Klaushofer K, Resch H, Pietschmann P. How long women with postmenopausal osteoporosis should be treated with a bisphosphonate? Horm Metab Res 2013 (epub ahead of print) IF:2.686

60. Pietschmann P. Editorial: Hyperparathyroidism. Wien Med Wochenschr (2013) 163:389-390

61. Kerschan-Schindl K, Mikosch P, Obermayer-Pietsch B, Gasser RW, Dimai HP, Fahrleitner-Pammer A, Dobig H, Roschger P, Preisinger E, Klaushofer K, Resch H, Pietschmann P. Current controversies in clinical management of postmenopausal osteoporosis. Exp Clin Endocrinol Diab, accepted IF: 1.555

22

BOOK CHAPTERS:

1. Schiller C, Katzgraber F, Redlich K, Pietschmann P, Peterlik M: Multi-hormonal effects on osteoclast formation and function. In: De Bellis A, Schipani E (eds): Future trends in endocrinology. Frontiers in endocrinology. Ares-Serono Symposia Publications, 1995, vol 14, pp 5 - 13

2. Pietschmann P: Exercise and physical therapy in the prevention and treatment of

osteoporosis. In: Bröll H, Dambacher MA (eds): Osteoporosis: A guide to diagnosis and treatment. Rheumatology. Basel, Karger, 1996, vol 18, pp 265 – 270

3. Erlacher L, Pietschmann P: Begleittherapie der Osteoporose. In: Bröll H,

Dambacher MH (eds) Osteoporose aktuell: Grundlagen, Diagnostik, Therapie, Spitta Verlag, Balingen, 1998, pp. 128 - 134

4. Pietschmann P: Osteoporose beim Mann. In: Plas E, Riedl CR, Pflüger H (eds):

Andropause: Mythos oder Realität? Georg Thieme Verlag, Stuttgart, 2000, pp. 39 - 42

5. Kudlacek S, Stohlawetz P, Hahn P, Willvonseder R, Pietschmann P: Surface

markers and transendothelial migration of mononuclear cells from elderly subjects. In: Bertoni-Freddari C, Niedermüller H (eds): Current Concepts in Experimental Gerontology, Facultas Universitätsverlag, Wien, 2001, pp 47 – 53

6. Pietschmann P, Gruber R, Peterlik M: Pathophysiology and aging of bone. In:

Grampp S (ed) Radiology of Osteoporosis, Springer Verlag, 2002, pp. 3 - 24

7. Pietschmann P, Resch H, Peterlik M: Etiology and pathogenesis of osteoporosis. In: An YH (ed) Orthopaedic Issues in Osteoporosis, CRC press, Boca Raton, 2003, pp. 3 – 18

8. Pietschmann H, Pietschmann P: Bildnerisches Gestalten als Ergotherapie in der

Geriatrie unter besonderer Berücksichtigung der Demenzen. In: Vanecek E, Wenninger-Brenn C (eds) Kunst - Medizin – Therapie, WUV Universitätsverlag, Wien, 2003, pp. 99 – 116

9. Pietschmann P, Smolen JS. Rheumatische Erkrankungen. In: S. Schwarz, O.

Förster, M. Peterlik, K. Schauenstein, Georg Wick (Eds). Pathophysiologie – Molekulare, Zelluläre, Systemische Grundlagen von Krankheiten. Verlag Maudrich 2007, Kapitel 26: 1-21.

10. Gruber R, Pietschmann P, Peterlik M. Introduction to bone development,

remodelling and repair. In: Grampp S. (ed.): Radiology of Osteoporosis. Springer Verlag 2008, pp 1-24.

23

11. Pietschmann P, Gruber R, Peterlik M. Pathophysiology and aging of bone. In:

Grampp S. (ed.) Radiology of Osteoporosis, Springer Verlag 2008, pp.25-42

12. Patsch J, Pietschmann P. Knochenerkrankungen. In: Böhmer F, Füsgen I (eds) Geriartrie: der ältere Patient mit seinen Besonderheiten. Böhlau Verlag Köln –Weimar – Wien 2008, pp.397-406.

13. Pietschmann P, Patsch J. RANKL und Osteoprotegerin in der Pathogenese der

Osteoporose. In: Pietschmann P (ed.): Osteoimmunologie – Zytokine und Biologika in der Osteologie. 2. Auflage, UNI-MED Verlag AG Bremen – London – Boston 2011, pp.66-71.

14. Heindl A, Schepelmann M, Ecker R, Pietschmann P, Ellinger I, Seewald AK,

Thalhammer T. Towards the automated detection and characterization of osteoclasts in microscopic images. In: Pietschmann P (ed). Principles of Osteoimmunology – Molecular Mechanisms and Clinical Applications. SpringerWienNewYork 2011, pp. 27-48

15. Azizi-Semrad U, Pietschmann P, Willheim M. Effects of vitamin D in the immue

system. In: Pietschmann P (ed). Principles of Osteoimmunology – Molecular Mechanisms and Clinical Applications. SpringerWienNewYork 2011, pp. 63-90

16. Bertl K, Pietschmann P, Matejka M. Osteoimmunological aspects of peridontal

diseases. In: Pietschmann P (ed). Principles of Osteoimmunology – Molecular Mechanisms and Clinical Applications. SpringerWienNewYork 2011, pp. 241-267

17. Erlacher L, Azizi-Semrad U, Pietschmann P. Bausteine des Bindegewebes. In:

Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie. Springer WienNewYork 2012, pp. 9-13

18. Pietschmann P, Kerschan-Schindl K. Osteoporose. In: Kautzky-Willer A (ed.).

Gendermedizin. Böhlau Verlag Wien-Köln-Weimar 2012, pp. 103-122

19. Pietschmann P., K. Kerschan-Schindl, K. Redlich, M. Aringer. Osteoporose und weitere metabolische Osteopathien. In: Stummvoll G, Pretterklieber ML, Kainberger F (eds). Bewegung und Leistung, Schmerz (MCW Block 21, 10. Auflage). Facultas Verlag 2013, pp. 148-162

20. Pietschmann P. Autoimmunendokrinologie. In: Ludvik B, Bischof M, Kraupp M,

Luger A (eds). Endokrinologie und Stoffwechsel (MCW Block 10). Facultas 7. Auflage, Facultas Verlag 2013, pp. 18-25

24

21. Pietschmann P, Nanoff C, Dudczak R, Kainberger F. Knochen- und Kalzium-Stoffwechsel. In: Ludvik B, Bischof M, Kraupp M, Luger A (eds). Endokrinologie und Stoffwechsel (MCW Block 10).7. Auflage, Facultas Verlag 2013, pp. 204-217

22. Patsch J, Pietschmann P. Degenerative und altersassoziierte Erkrankungen. In:

Marian B (ed). Krankheit, Krankheitsursachen und –bilder (MCW Block 8). Facultas 7. Auflage, Facultas Verlag 2013, pp.422-430

23. Pietschmann P. Pathophysiologie des Alterns. In: Dorner TE (ed.) Public Health.

Von den Gesundheitsbedürfnissen der Gesellschaft zu klinischen Implikationen. (MCW Block 22/23) Facultas WUV 2013, pp. 251-254

24. Sipos W, Föger-Samwald U, Pietschmann P. Supporting apparatus of vertebrates:

skeleton and bones. In: Jensen-Jarolim E (ed). Comparative Medicine – Anatomy and Physiology. Springer Verlag 2014, pp.35-44

BOOKS EDITED: Pietschmann P. Principles of Osteoimmunology – Molecular Mechanisms and Clinical Applications. SpringerWienNewYork 2011 Pietschmann P. Osteoimmunologie – Zytokine und Biologika in der Osteologie. UNI-MED Verlag AG Bremen – London – Boston 2012

25

FURTHER SELECTED PUBLICATIONS:

1. Pietschmann P (1990) Osteocalcin. Ärztl Lab 36: 334

2. Pietschmann P (1990) Fettstoffwechselstörungen bei Diabetes mellitus. Prakt Arzt 44: 1467-1472

3. Pietschmann P (1993) Glukokortikoid-induzierte Osteoporose. Osteoporose News

6: 1 - 4

4. Pietschmann P (1994) Osteoporose beim Mann. Forum Dr. med 18; 8: 36 – 39

5. Pietschmann P, Menschik M (1995) Therapie der Osteoporose beim Mann. Forum Dr. med 19; 18: 34 – 37

6. Pietschmann P (1997) Osteoporose aus der Sicht des Internisten. Hausarzt 8/4: 7 –

11

7. Pietschmann P (1997) Steroide, Endokrinopathien und Osteoporose. Collegium publicum 2, 18.10.1997, 12 – 13

8. Pietschmann P, Pietschmann F, Ogris E (1998) Morbus Paget. Der Mediziner 7:

32 – 35

9. Pietschmann P (1998) Therapie der Osteoporose. Forum Dr. med. 22; 10: 24 - 27

10. Lernbass I, Peterlik M, Pietschmann P (1999) Osteoporose bei rheumatischen Erkrankungen. Promed 7-8/99: 24 – 30

11. Pietschmann P, Redlich K (1999) Posttransplantationsosteopathie. Osteologie

forum 5: 59 – 62

12. Initiative Arznei & Vernunft. Osteoporose. Oktober 1999

13. Pietschmann P, Erlacher L (2000) Osteoarthrose: Pathophysiologie, Klinik und Therapie. Promed 11/2000: 25 – 28

14. Kudlacek S, Willvonseder R, Pietschmann P (2004) Der Mann mit Osteoporose.

Der Mediziner 10: 20 – 23

15. Initiative Arznei & Vernunft. Osteoporose. 2. Auflage, Oktober 2005

16. Dobnig H, Erlacher L, Finkenstedt G, Klaushofer K, Pietschmann P, Roschger P, Bröll H, Resch H: Osteoporose – Bedeutung der Knochenqualität.Österreichische Ärztezeitung. Supplementum, Februar 2006: 1-8

26

17. Dimai HP, Elnekheli M, Finkenstedt G, et al (2006) Alendronat – ein

anspruchsvolles Molekül-Fragen aus der Praxis. Internationale Zeitschrift für ärztliche Fortbildung. Mai, Nr. 21

18. Konsensus-Statement: Osteoporose 75+. CliniCum Sonderausgabe September

2007

19. Konsensus: Osteoporose-Prävention & Therapie. Österreichische Ärztezeitung Supplementum, August 2007

20. Patsch J, Pietschmann P (2007) Controversial question- does histomorphometry

still have a role to play?. Medicographia 29(2): 151

21. Resch H, Wögerbauer T, Pietschmann P (2007) Management der Osteoporose – Diagnose, Standards, Therapie. Österreichische Ärztezeitung 10 (25.Mai): 30-39

22. Burckhardt P, Concin H, Dimai H, Dobnig H, Erlacher L, Finkensedt G, Gasser

R, Holzer G, Klaushofer K, Kotz R, Kraenzlin M, Minne HW, Obermayer-Pietsch B, Peichl P, Pietschmann P, Roschger P, Schütz W, Sieghart S, Windhager R (2007) Med ahead consensus-Osteoporose- Stellenwert der PTH-Therapie. Österreichische Ärztezeitung (Suppl März): 3-10

23. Patsch J, Pietschmann P 2007). Wenn Männerknochen brechen: Die Osteoporose

des Mannes. Österreichische Ärztezeitung 19 (10. Oktober): 72

24. Pietschmann P, Patsch J (2008) Focus Osteoporose: Osteoporose beim Mann. Fakten der Rheumatologie 3: 17-18

25. Pietschmann P, Steiner M (2009) 100 Jahre Geriatrie in Österreich. Geriatrie (Geriatrie Praxis in Österreich) 5-6: 22-23

26. Konsensus-Statement: Schmerzmessung und Schmerztherapie im Alter. Schmerz

Nachrichten Nr. 3a, 2009

27. Pietschmann, P. and E. Maldonado (2009). Metabolismus und Wirkmechanismen – Update zur Physiologie des Vitamin-D-Hormons. Spectrum Osteoporose 1/09:13-14.

28. Maldonado E., and P. Pietschmann. (2009). Pathophysiologie der Osteoporose. Geriatrie Praxis Österreich. 3/09

29. Psaier S, Pietschmann P (2010) Osteoporose – eine geschlechtspezifische Erkrankung beider Geschlechter. ÖAZ 23 (64 Jg.): 1354-1358

30. Arznei & Vernunft. Osteoporose- Knochenbruch-Krankheit. 3. Auflage, Mai 2010

27

31. Bröll H, Resch H, Bernecker P, Blauth M, Concin H, Dimai P, Dobnig H,

Erlacher L, Fahrleitner-Pammer A, Gasser R, Herold M, Holzer G, Huber J, Jilma B, Kraenzlin M, Leeb B, Leodolter S, Minne H, Patsch J, Pietschmann P, Preisinger E, Windhager R. Experten Statement (2011) Denosumab-aktueller Stellenwert in der Osteoporosebehandlung. Österreichische Ärztezeitung, Supplementum (Juni 2011): 2-7

32. Bröll J, Resch H, Bernecker P, Concin H, Dimai P, Dobnig H, Erlacher L, Fahrleitner-Pammer A, Gasser R, Herold M, Hofbauer LC, Holzer G, Huber J, Köller M, Kränzlin M, Leodolter S, Maier R, Peichl PF, Peterlik M, Pietschmann P, Preisinger E, Rieder A, Wicker A, Windhager R (2011) Konsensus Osteoporose - Prävention & Therapie. Österreichische Ärztezeitung Supplementum (Dezember 2011):3-16

33. Pietschmann P, Föger-Samwald U (2012) FRAX® - Was ist das? Skriptum Kongressjournal der Wiener Medizinischen Wochenschrift 12:18-19